Abstract
Background
Clinical data for bacterial coinfection of the lower respiratory tract in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD) are scarce. This study aims to assess the prevalence of bacterial coinfection and clinical features in NTM-PD patients.
Methods
This retrospective study screened 248 patients with NTM-PD who underwent bronchoscopy between July 2020 and July 2022, from whom newly diagnosed NTM-PD patients were analyzed. Bacterial culture using bronchial washing fluid was performed at the time of NTM-PD diagnosis.
Results
In the 180 patients (median age 65 years; 68% female), Mycobacterium avium complex (86%) was the most frequent NTM isolated. Bacterial coinfections were detected in 80 (44%) patients. Among them, the most common bacterium was Klebsiella pneumoniae (n=25/80, 31.3%), followed by Pseudomonas aeruginosa (n=20/80, 25%) and Staphylococcus aureus (n=20/80, 25%). Compared with NTM-PD patients without bacterial coinfections, patients with bacterial coinfections showed more frequent extensive lung involvement (33% vs. 1%, p<0.001). Additionally, compared with NTM-PD patients without P. aeruginosa infection, those with P. aeruginosa infection were older (74 years vs. 64 years, p=0.001), had more frequent respiratory symptoms (cough/excessive mucus production 70% vs. 38%, p=0.008; dyspnea 30% vs. 13%, p=0.047), and had extensive lung involvement (60% vs. 9%, p<0.001).
Conclusion
Less than half of patients with newly diagnosed NTM-PD had bacterial coinfections, linked to extensive lung involvement. Specifically, P. aeruginosa coinfection was significantly associated with older age, more frequent respiratory symptoms, and extensive lung involvement.
Keywords: Nontuberculous Mycobacteria, Bacterial Coinfection, Bronchiectasis, Bronchiectasis Severity, Pseudomonas Aeruginosa
Graphic Abstract

Introduction
Nontuberculous mycobacteria (NTM), a diverse group of organisms excluding Mycobacterium leprae and Mycobacterium tuberculosis complex, are ubiquitous environmental inhabitants found in soil and water [1]. While often harmless, NTM can cause various human diseases, with pulmonary disease being the most common manifestation [2]. Currently, there is a global trend of increasing incidence in nontuberculous mycobacterial pulmonary disease (NTM-PD), particularly in developed countries including South Korea [3,4].
NTM-PD presents in a variety of clinical manifestations over a long time period after NTM acquisition [1,5]. One of these manifestations is that the bronchi become more susceptible to chronic, slowly progressive inflammation, potentially compromising their structural integrity [6]. Furthermore, the compromised airways in NTM-PD patients are more susceptible to secondary infections, and previous studies have indicated that 12% to 45% of patients with Mycobacterium avium complex pulmonary disease (MAC-PD) concurrently exhibit bacterial infections [7-9]. Although prior investigations have consistently identified coinfection with bacterial pathogens alongside NTM acquisition or disease course, these studies have been limited by the use of sputum culture-based bacterial detection, small numbers of patients, and differences in research objectives and testing timing depending on study design [7-10].
This study aims to investigate the prevalence and clinical significance of coinfection with pathogenic microorganisms obtained through bronchoscopy on the initial diagnosis of NTM-PD.
Materials and Methods
1. Study population
We retrospectively reviewed patients who were diagnosed with NTM-PD by bronchoscopic evaluation at Samsung Changwon Hospital (a 761-bed tertiary referral hospital in Changwon, South Korea), between July 2020 and July 2022. A total of 248 NTM-PD patients was initially considered. Among them, 68 were excluded due to absence of NTM identification test (n=31) or previous diagnosis of NTM-PD (n=37). Consequently, 180 patients newly diagnosed with NTM-PD were included in this study (Figure 1). All patients met the clinical and radiologic criteria (nodular or cavitary opacities on chest radiograph, or computed tomography [CT] scan showing bronchiectasis with multiple small nodules) for the diagnosis of NTM-PD with positive culture results from at least one bronchial washing [2].
Fig. 1.
Patient flow chart. NTM-PD: nontuberculous mycobacterial pulmonary disease; NTM: nontuberculous mycobacteria.
2. Bronchoscopic procedures
All bronchoscopy procedures were performed by attending physicians. Sedatives including 0.05 to 0.07 mg/kg of midazolam and/or 0.2 to 0.5 μg/kg of fentanyl were administered intravenously to achieve adequate sedation prior to the procedure [11,12]. All procedures were performed transnasally or transorally under local anesthesia. In all patients, complete airway inspection was performed, and bronchial washing was conducted at any involved lesion that was suggestive of NTM-PD on chest CT prior to bronchoscopy evaluation. Sterile normal saline (20 to 40 mL) was injected into the involved lesion, and the specimen was aspirated via bronchoscope.
3. Microbiologic evaluation
All bronchial washing specimens were examined for both mycobacterial and bacterial pathogens. All bronchial washing specimens were cultured using both solid (3% Ogawa medium; Korean Institute of Tuberculosis, Cheongju, Korea) and liquid (BACTEC 960 Mycobacterial Growth Indicator Tube, Becton Dickinson, Sparks, MD, USA) media [13].
All specimens were also examined for bacterial pathogens using the Gram stain method, and bacterial identification was performed using automatic VITEK 2 diagnostic systems (bioMérieux Inc., Hazelwood, MO, USA).
4. Data collection
We retrospectively collected patient data including age, sex, body mass index (BMI), smoking history, respiratory symptoms of NTM-PD (e.g., cough, excessive mucus production, dyspnea, or hemoptysis), presence of underlying pulmonary disease, and bronchial washing specimen results. The laboratory findings, including white blood cell count, C-reactive protein as an inflammatory marker, and albumin as an indicator reflecting overall nutritional status, were assessed.
Radiological phenotypes of NTM-PD were assessed and classified into fibrocavitary form, nodular bronchiectatic form, and unclassifiable form [14]. We defined coinfection as the detection of pathogenic microorganisms other than NTM in at least one bronchial washing bacterial culture. Extensive lung involvement was defined if three or more lobes are involved, as assessed by CT scan, as previously reported [15].
5. Ethics
This study was approved by the Institutional Review Board of Samsung Changwon Hospital (reference no. 2024-01-002). The requirement for informed consent was waived due to the retrospective nature of the study and the data were anonymized and de-identified prior to analysis.
6. Statistical analysis
Data are presented as median with interquartile range (IQR) or number (%) of patients. Categorical variables were compared using Pearson’s chi-square test or Fisher’s exact test [16]. Continuous variables were compared using the Mann-Whitney U test [17]. A p-value <0.05 was considered statistically significant. Statistical analyses were conducted using SPSS version 23.0 for Windows (IBM Co., Chicago, IL, USA) [18].
Results
1. Baseline characteristics of NTM-PD patients
A total of 180 patients was included, and the baseline characteristics are shown in Table 1. The median age of patients was 65 years (IQR, 56 to 74), 122/180 (67.8%) were female, and the median BMI was 20.4 kg/m2 (IQR, 18.9 to 22.4). Most patients were non-smokers (n=139/180, 77.2%) and 22/180 patients (12.2%) had diabetes mellitus as a comorbidity. The most common predominant symptoms were cough with or without excessive mucus production (n=75/180, 41.7%), followed by dyspnea (n=26/180, 14.4%); however, 82/180 patients (45.6%) were asymptomatic at the time of diagnosis. Regarding radiological phenotypes of NTM-PD, nodular bronchiectatic form (n=151/180, 83.9%) was most often observed, followed by fibrocavitary form (n=22/180, 12.2%) and unclassifiable form (n=7/180, 3.9%). Almost all patients (n=169/180, 93.9%) had bronchiectasis, and tuberculous-destroyed lung, parenchymal destruction due to previous tuberculosis infection, was found in 22/180 patients (12.2%). Median white blood cell, C-reactive protein, and albumin levels were 5,760/μL, 1.4 mg/dL, and 4.4 g/dL, respectively.
Table 1.
Baseline characteristics of nontuberculous mycobacterial pulmonary disease patients who underwent bronchoscopy (n=180)
| Characteristic | Value |
|---|---|
| Age, yr | 65 (56–74) |
| Female sex | 122 (67.8) |
| Body mass index, kg/m2 | 20.4 (18.9–22.4) |
| Smoking history | |
| Non-smoker | 139 (77.2) |
| Comorbidity | |
| Diabetes mellitus | 22 (12.2) |
| Respiratory symptoms* | |
| Cough with or without excessive mucus production | 75 (41.7) |
| Dyspnea | 26 (14.4) |
| Hemoptysis | 23 (12.8) |
| Asymptomatic | 82 (45.6) |
| Radiological phenotypes | |
| Nodular bronchiectatic form | 151 (83.9) |
| Fibrocavitary form | 22 (12.2) |
| Unclassifiable | 7 (3.9) |
| Underlying pulmonary disease* | |
| Bronchiectasis | 169 (93.9) |
| Tuberculous-destroyed lung | 22 (12.2) |
| Emphysema | 12 (6.7) |
| Interstitial lung disease | 4 (2.2) |
| Laboratory findings | |
| White blood cell, /μL | 5,760 (4,753–6,863) |
| C-reactive protein, mg/dL | 1.4 (0.4–6.4) |
| Albumin, g/dL | 4.4 (4.1–4.7) |
Values are presented as median (interquartile range) or number (%).
Cases are duplicated.
2. NTM species cultured from bronchial washing fluid
Table 2 shows the NTM species cultured. The most common species was Mycobacterium intracellulare (n=115/180, 63.9%), followed by M. avium (n=36/180, 20.0%) and Mycobacterium abscessus (n=18/180, 10.0%). Mixed infections were found in 4/180 patients (2.2%) and included M. avium/M. intracellulare (n=2), M. avium/Mycobacterium kansasii (n=1), and M. intracellulare/M. abscessus subspecies massiliense (n=1).
Table 2.
NTM species cultured from bronchial washing fluid (n=180)
| NTM species | No. (%) |
|---|---|
| Mycobacterium avium complex | |
| M. avium | 36 (20.0) |
| M. intracellulare | 115 (63.9) |
| M. abscessus | |
| M. abscessus subspecies abscessus | 7 (3.9) |
| M. abscessus subspecies massiliense | 11 (6.1) |
| M. kansasii | 6 (3.3) |
| M. mucogenicum | 1 (0.5) |
| Mixed infection | |
| M. avium+M. intracellulare | 2 (1.1) |
| M. avium+M. kansasii | 1 (0.5) |
| M. intracellulare+M. abscessus subspecies massiliense | 1 (0.5) |
NTM: nontuberculous mycobacteria.
3. Bacterial culture from bronchial washing fluid
Of the 180 patients with newly diagnosed NTM-PD by bronchial washing, 80/180 (44.4%) had bacteria cultured from bronchial washing fluid, and the species of bacteria are summarized in Table 3. Most (n=73/80, 91.2%) had a single bacterium, and 7/80 (8.8%) had multiple bacteria species. The most commonly identified species were Klebsiella species (n=29/80, 36.3%) including 25 cases of Klebsiella pneumoniae, followed by Pseudomonas species (n=22/80, 27.5%) including 20 cases of Pseudomonas aeruginosa, and then by Staphylococcus aureus (n=20/80, 25.0%).
Table 3.
Bacteria species cultured from bronchial washing fluid (n=180)
| Variable | No. (%) |
|---|---|
| Patients with detected bacteria | 80 (44.4) |
| Single bacterium | 73 |
| Multiple bacteria | 7 |
| Bacteria species* | 80 |
| Klebsiella species | 29 (36.3) |
| Klebsiella pneumoniae | 25 |
| Klebsiella oxytoca | 4 |
| Pseudomonas species | 22 (27.5) |
| Pseudomonas aeruginosa | 20 |
| Pseudomonas fluorescens | 1 |
| Pseudomonas putida | 1 |
| Staphylococcus aureus | 20 (25.0) |
| MSSA | 16 |
| MRSA | 4 |
| Enterobacter species | 5 (6.3) |
| Enterobacter cloacea | 3 |
| Enterobacter aerogenes | 2 |
| Haemophilus influenzae | 3 (3.8) |
| Escherichia coli | 2 (2.5) |
| Streptococcus pneumoniae | 2 (2.5) |
| Acinetobacter baumannii | 2 (2.5) |
| Morganella morganii | 1 (1.3) |
| Enterococcus species | 1 (1.3) |
Cases are duplicated.
MSSA: methicillin-sensitive Staphylococcus aureus; MRSA: methicillin-resistant Staphylococcus aureus.
4. Comparison of clinical characteristics of NTM-PD patients according to bacteria
Table 4 shows the comparison of clinical characteristics of NTM-PD patients with or without bacteria identified from bronchial washing fluid. Compared with NTM-PD patients without bacteria, those with bacteria were more likely to have extensive disease with three or more lobes involved (n=26 vs. 1, p<0.001). Patients with the fibrocavitary form of NTM-PD tended to be without bacterial coinfection (p=0.038).
Table 4.
Comparison of clinical characteristics of nontuberculous mycobacterial pulmonary disease patients with or without bacteria cultured from bronchial washing fluid
| Characteristic | Bacteria cultured |
p-value | |
|---|---|---|---|
| Yes (n=80) | No (n=100) | ||
| Age, yr | 67 (58–75) | 64 (56–73) | 0.110 |
| Female sex | 53 (66.3) | 69 (69.0) | 0.749 |
| Body mass index, kg/m2 | 20.8 (19.0–23.3) | 20.4 (18.4–21.7) | 0.201 |
| Non-smoker | 60 (75.0) | 79 (79.0) | 0.593 |
| Comorbidity | |||
| Diabetes mellitus | 11 (13.8) | 11 (11.0) | 0.650 |
| Underlying pulmonary disease* | |||
| Emphysema | 4 (5.0) | 8 (8.0) | 0.552 |
| Interstitial lung disease | 1 (1.3) | 3 (3.0) | 0.630 |
| Bronchiectasis | 77 (96.3) | 92 (92.0) | 0.350 |
| Tuberculous-destroyed lung | 10 (12.5) | 12 (12.0) | >0.999 |
| Respiratory symptoms* | |||
| Cough with or without excessive mucus production | 38 (47.5) | 37 (37.0) | 0.173 |
| Dyspnea | 13 (16.3) | 13 (13.0) | 0.670 |
| Hemoptysis | 9 (11.3) | 14 (14.0) | 0.657 |
| Asymptomatic | 32 (40.0) | 50 (50.0) | 0.228 |
| Radiological phenotypes | |||
| Nodular bronchiectatic form | 71 (88.8) | 80 (80.0) | 0.153 |
| Fibrocavitary form | 5 (6.3) | 17 (17.0) | 0.038 |
| Unclassifiable | 4 (5.0) | 3 (3.0) | 0.702 |
| No. of involved lobes ≥3 | 26 (32.5) | 1 (1.0) | <0.001 |
| Laboratory findings | |||
| White blood cell, /μL | 6,050(4,725–6770) | 5,610 (4,778–6,948) | 0.491 |
| C-reactive protein, mg/dL | 1.3 (0.4–6.8) | 1.4 (0.4–5.9) | 0.901 |
| Albumin, g/dL | 4.4 (4.2–4.6) | 4.5 (3.9–4.7) | 0.963 |
Values are presented as median (interquartile range) or number (%).
Cases are duplicated.
Compared with NTM-PD patients without P. aeruginosa, those with P. aeruginosa were older (74 years vs. 64 years, p=0.001), tended to be male (60.0 % vs. 28.8%, p=0.009), were ever-smokers (55.0% vs. 18.8%, p<0.001), and had respiratory symptoms including cough with or without excessive mucus production (70.0% vs. 38.1%, p=0.008), dyspnea (30.0% vs. 12.5%, p=0.047), and extensive lung disease (60.0% vs. 9.4%, p<0.001) (Table 5). In contrast, patients with K. pneumoniae had no differences compared with those without K. pneumoniae except in C-reactive protein level (Supplementary Table S1). Also, patients with S. aureus did not differ from those without S. aureus (Supplementary Table S2).
Table 5.
Comparison of clinical characteristics of nontuberculous mycobacterial pulmonary disease patients with or without Pseudomonas aeruginosa cultured from bronchial washing fluid
| Characteristic |
Pseudomonas aeruginosa
|
p-value | |
|---|---|---|---|
| Yes (n=20) | No (n=160) | ||
| Age, yr | 74 (65–80) | 64 (56–73) | 0.001 |
| Female sex | 8 (40.0) | 114 (71.3) | 0.009 |
| Body mass index, kg/m2 | 21.0 (18.9–23.3) | 20.4 (19.0–22.0) | 0.757 |
| Non-smoker | 9 (45.0) | 130 (81.3) | <0.001 |
| Comorbidity | |||
| Diabetes mellitus | 3 (15.0) | 19 (11.9) | 0.716 |
| Underlying pulmonary disease* | |||
| Emphysema | 3 (15.0) | 9 (5.6) | 0.134 |
| Interstitial lung disease | 1 (5.0) | 3 (1.9) | 0.378 |
| Bronchiectasis | 19 (95.0) | 150 (93.8) | >0.999 |
| Tuberculous-destroyed lung | 2 (10.0) | 20 (12.5) | >0.999 |
| Respiratory symptoms* | |||
| Cough with or without excessive mucus production | 14 (70.0) | 61 (38.1) | 0.008 |
| Dyspnea | 6 (30.0) | 20 (12.5) | 0.047 |
| Hemoptysis | 2 (10.0) | 21 (13.1) | >0.999 |
| Asymptomatic | 6 (30.0) | 76 (47.5) | 0.159 |
| Radiological phenotypes | |||
| Nodular bronchiectatic form | 18 (90.0) | 133 (83.1) | 0.746 |
| Fibrocavitary form | 1 (5.0) | 21 (13.1) | 0.475 |
| Unclassifiable | 1 (5.0) | 6 (3.8) | 0.568 |
| No. of involved lobes ≥3 | 12 (60.0) | 15 (9.4) | <0.001 |
| Laboratory findings | |||
| White blood cell, /μL | 6,310 (5,180–7,180) | 5,690 (4,710–6,815) | 0.139 |
| C-reactive protein, mg/dL | 2.2 (1.1–9.8) | 1.1 (0.4–5.6) | 0.118 |
| Albumin, g/dL | 4.3 (4.0–4.5) | 4.5 (4.1–4.7) | 0.235 |
Values are presented as median (interquartile range) or number (%).
Cases are duplicated.
Discussion
In this study, we evaluated the microorganisms in lower respiratory tracts of patients with NTM-PD using bronchoscopic washing fluid analysis. Most NTM-PD patients had nodular bronchiectatic form (n=151/180, 83.9%), and M. intracellulare was the most frequent cause of NTM-PD (n=115/180, 63.9%). Less than half of NTM-PD patients (n=80/180, 44.4%) had accompanying bacteria, among which the most common species was K. pneumoniae (n=25/80, 31.3%), followed by P. aeruginosa (n=20/80, 25.0%) and S. aureus (n=20/80, 25.0%). Patients with NTM-PD with extensive involvement tended to have accompanying bacteria including P. aeruginosa. In particular, NTM-PD patients with P. aeruginosa were older, predominantly male and ever-smokers, with extensive lobe involvement and tended to complain of respiratory symptoms such as cough with or without excessive mucus production or dyspnea.
Although there are several studies regarding the microbiome in bronchiectasis [19,20], data regarding microorganisms in the lower respiratory tract of NTMPD patients are limited [21]. In a study based on analysis of repeated sputum samples, Fujita et al. [8] suggested that patients with MAC-PD frequently had chronic coinfections of S. aureus and P. aeruginosa (124/275, 45.1%). Yamasaki et al. [22] evaluated the microbiome from bronchial alveolar lavage samples in bronchiectasis patients and found that anaerobes were abundant in patients with NTM-PD compared to those without NTM-PD. Sulaiman et al. [23] assessed microbiomes in subset of patients with bronchiectasis and found no significant differences in bacterial load or diversity between those with NTM and without. However, these studies analyzed microbiome composition and did not assess the clinical aspects of NTM-PD. Although our study analyzed the bacteria with conventional culture techniques, we also systematically evaluated lower respiratory bacteria obtained through bronchoscopy in a relatively large number of NTM-PD patients; this work suggests that NTM-PD and bacterial coinfection associated with extensive lung disease and P. aeruginosa-NTM-PD coinfection is associated with poorer clinical conditions.
In patients with NTM-PD, bronchiectasis is the most relevant comorbid respiratory disease, and nodular bronchiectatic form was the most common phenotype [4,14,24]. In the present study, almost the whole NTM-PD population (93.9%) had bronchiectasis. In contrast, NTM was reported in a wide range of bronchiectasis cohorts (8.8% to 63.0%) [25-27]. Pseudomonas infection is a biomarker of severity in bronchiectasis [15,28]. Although NTM and Pseudomonas infections are frequent and important in bronchiectasis populations, there are limited data of the impact of Pseudomonas infection on the clinical course of NTM-PD. A Taiwanese study suggested association of concomitant NTM and P. aeruginosa infection with poorer clinical outcome including the greatest decline in pulmonary function and worst disease severity with more frequent exacerbations [29]. A Japanese study also showed impaired quality of life in patients with NTM- P. aeruginosa coinfection in a population with MAC-PD [30]. Our study results consistently demonstrated that NTM- P. aeruginosa coinfection was distinctively associated with more extensive lung disease with worse respiratory symptoms compared with NTM-PD without P. aeruginosa coinfection. In contrast, NTM-K. pneumoniae and NTM-S. aureus coinfections did not have a clinical effect on NTM-PD patients.
Interestingly, this study showed male and ever-smoker predominance in P. aeruginosa infection among NTM-PD patients. However, Vidaillac et al. [31] evaluated gender differences in bronchiectasis and suggested P. aeruginosa to be the predominant pathogen in females rather than males. Additionally, a recent Chinese study found that the prevalence of P. aeruginosa infection was greater in females than males in elderly patients with bronchiectasis [32]. Because our study only analyzed NTM-PD patients who could undergo bronchoscopy, a selection bias could exist; the differences in study populations (bronchiectasis patients vs. NTM-PD patients) could account for the discrepancies between previous studies and our study. However, there is much evidence that smoke exposure is associated with increased virulence of P. aeruginosa and impaired bacterial clearance after P. aeruginosa infection [33,34]. Smoking is also a predisposing factor for NTM-PD [35], and there is a possibility that smoking is associated with increasing risk of P. aeruginosa coinfection in patients with NTM-PD.
This study has several limitations. First, the history of antibiotics administration before bronchoscopic procedure was not evaluated and could affect bacterial culture. Second, this retrospective study was conducted at a single center, which might limit its generalizability. Multi-center prospective studies of prevalence and the clinical impact of bacterial coinfections with NTM-PD are warranted. Third, this study only enrolled NTM-PD patients who underwent bronchoscopy, and there could be a selection bias leading to an unrepresentative NTM-PD patient population.
In conclusion, less than half of NTM-PD patients had bacterial coinfections, and they had more extensive lung involvement. Additionally, patients with NTM-P. aeruginosa coinfection had significantly more frequent respiratory symptoms and extensive lung involvement. Further studies with larger cohorts and a prospective design are needed to validate and expand upon these findings.
Acknowledgments
This study was presented at the 2023 European Respiratory Society International Congress.
Footnotes
Authors’ Contributions
Conceptualization: Shin B. Methodology: Moon SM, Shin B. Formal analysis: Moon SM, Shin B. Data curation: all authors. Funding acquisition: Moon SM. Project administration: Shin B. Validation: all authors. Investigation: all authors. Writing - original draft preparation: Moon SM, Shin B. Writing - review and editing: all authors. Approval of final manuscript: all authors.
Conflicts of Interest
No potential conflict of interest relevant to this article was reported.
Funding
This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (No. 2021R1G1A1093908).
The authors thank MID (Medical Illustration & Design) for providing excellent support with medical illustration.
Supplementary Material
Supplementary material can be found in the journal homepage (http://www.e-trd.org).
Comparison of clinical characteristics of NTM-PD patients with or without Klebsiella pneumoniae cultured from bronchial washing fluid.
Comparison of clinical characteristics of NTM-PD patients with or without Staphylococcus aureus cultured from bronchial washing fluid.
REFERENCES
- 1.Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416. doi: 10.1164/rccm.200604-571ST. [DOI] [PubMed] [Google Scholar]
- 2.Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Jr, Andrejak C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020;56:2000535. doi: 10.1183/13993003.00535-2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Brode SK, Daley CL, Marras TK. The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: a systematic review. Int J Tuberc Lung Dis. 2014;18:1370–7. doi: 10.5588/ijtld.14.0120. [DOI] [PubMed] [Google Scholar]
- 4.Ko RE, Moon SM, Ahn S, Jhun BW, Jeon K, Kwon OJ, et al. Changing epidemiology of nontuberculous mycobacterial lung diseases in a tertiary referral hospital in Korea between 2001 and 2015. J Korean Med Sci. 2018;33:e65. doi: 10.3346/jkms.2018.33.e65. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Moon SM, Jhun BW, Baek SY, Kim S, Jeon K, Ko RE, et al. Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease. Respir Med. 2019;151:1–7. doi: 10.1016/j.rmed.2019.03.014. [DOI] [PubMed] [Google Scholar]
- 6.Fujita J, Ohtsuki Y, Suemitsu I, Shigeto E, Yamadori I, Obayashi Y, et al. Pathological and radiological changes in resected lung specimens in Mycobacterium avium intracellulare complex disease. Eur Respir J. 1999;13:535–40. doi: 10.1183/09031936.99.13353599. [DOI] [PubMed] [Google Scholar]
- 7.Urabe N, Sakamoto S, Sano G, Ito A, Homma S. Characteristics of patients with bronchoscopy-diagnosed pulmonary Mycobacterium avium complex infection. J Infect Chemother. 2018;24:822–7. doi: 10.1016/j.jiac.2018.06.014. [DOI] [PubMed] [Google Scholar]
- 8.Fujita K, Ito Y, Hirai T, Kubo T, Togashi K, Ichiyama S, et al. Prevalence and risk factors for chronic co-infection in pulmonary Mycobacterium avium complex disease. BMJ Open Respir Res. 2014;1:e000050. doi: 10.1136/bmjresp-2014-000050. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Urabe N, Sakamoto S, Shimanuki Y, Kanokogi T, Motohashi T, Anzai N, et al. Impact of chronic co-infection in pulmonary Mycobacterium avium complex disease after treatment initiation. BMC Pulm Med. 2022;22:157. doi: 10.1186/s12890-022-01947-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Wang G, Stapleton JT, Baker AW, Rouphael N, Creech CB, El Sahly HM, et al. Clinical features and treatment outcomes of pulmonary Mycobacterium avium-intracellulare complex with and without coinfections. Open Forum Infect Dis. 2022;9:ofac375. doi: 10.1093/ofid/ofac375. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Kim SB, Lee WY, Lee JH, Lee SJ, Lee MK, Kim SH, et al. A variety of bacterial aetiologies in the lower respiratory tract at patients with endobronchial tuberculosis. PLoS One. 2020;15:e0234558. doi: 10.1371/journal.pone.0234558. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Minami D, Takigawa N, Watanabe H, Ninomiya T, Kubo T, Ohashi K, et al. Safety and discomfort during bronchoscopy performed under sedation with fentanyl and midazolam: a prospective study. Jpn J Clin Oncol. 2016;46:871–4. doi: 10.1093/jjco/hyw083. [DOI] [PubMed] [Google Scholar]
- 13.Leylabadlo HE, Kafil HS, Yousefi M, Aghazadeh M, Asgharzadeh M. Pulmonary tuberculosis diagnosis: where we are? Tuberc Respir Dis (Seoul) 2016;79:134–42. doi: 10.4046/trd.2016.79.3.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Koh WJ, Moon SM, Kim SY, Woo MA, Kim S, Jhun BW, et al. Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. Eur Respir J. 2017;50:1602503. doi: 10.1183/13993003.02503-2016. [DOI] [PubMed] [Google Scholar]
- 15.Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The bronchiectasis severity index: an international derivation and validation study. Am J Respir Crit Care Med. 2014;189:576–85. doi: 10.1164/rccm.201309-1575OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Bewick V, Cheek L, Ball J. Statistics review 8: qualitative data: tests of association. Crit Care. 2004;8:46–53. doi: 10.1186/cc2428. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat. 1947;18:50–60. [Google Scholar]
- 18.Masuadi E, Mohamud M, Almutairi M, Alsunaidi A, Alswayed AK, Aldhafeeri OF. Trends in the usage of statistical software and their associated study designs in health sciences research: a bibliometric analysis. Cureus. 2021;13:e12639. doi: 10.7759/cureus.12639. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Tunney MM, Einarsson GG, Wei L, Drain M, Klem ER, Cardwell C, et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med. 2013;187:1118–26. doi: 10.1164/rccm.201210-1937OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Rogers GB, van der Gast CJ, Cuthbertson L, Thomson SK, Bruce KD, Martin ML, et al. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax. 2013;68:731–7. doi: 10.1136/thoraxjnl-2012-203105. [DOI] [PubMed] [Google Scholar]
- 21.Thornton CS, Mellett M, Jarand J, Barss L, Field SK, Fisher DA. The respiratory microbiome and nontuberculous mycobacteria: an emerging concern in human health. Eur Respir Rev. 2021;30:200299. doi: 10.1183/16000617.0299-2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Yamasaki K, Mukae H, Kawanami T, Fukuda K, Noguchi S, Akata K, et al. Possible role of anaerobes in the pathogenesis of nontuberculous mycobacterial infection. Respirology. 2015;20:758–65. doi: 10.1111/resp.12536. [DOI] [PubMed] [Google Scholar]
- 23.Sulaiman I, Wu BG, Li Y, Scott AS, Malecha P, Scaglione B, et al. Evaluation of the airway microbiome in nontuberculous mycobacteria disease. Eur Respir J. 2018;52:1800810. doi: 10.1183/13993003.00810-2018. [DOI] [PubMed] [Google Scholar]
- 24.Loebinger MR, Quint JK, van der Laan R, Obradovic M, Chawla R, Kishore A, et al. Risk factors for nontuberculous mycobacterial pulmonary disease: a systematic literature review and meta-analysis. Chest. 2023;164:1115–24. doi: 10.1016/j.chest.2023.06.014. [DOI] [PubMed] [Google Scholar]
- 25.Aksamit TR, O’Donnell AE, Barker A, Olivier KN, Winthrop KL, Daniels ML, et al. Adult patients with bronchiectasis: a first look at the US Bronchiectasis Research Registry. Chest. 2017;151:982–92. doi: 10.1016/j.chest.2016.10.055. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Suska K, Amati F, Sotgiu G, Gramegna A, Mantero M, Ori M, et al. Nontuberculous mycobacteria infection and pulmonary disease in bronchiectasis. ERJ Open Res. 2022;8:00060-2022. doi: 10.1183/23120541.00060-2022. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Faverio P, Stainer A, Bonaiti G, Zucchetti SC, Simonetta E, Lapadula G, et al. Characterizing non-tuberculous mycobacteria infection in bronchiectasis. Int J Mol Sci. 2016;17:1913. doi: 10.3390/ijms17111913. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Vidaillac C, Chotirmall SH. Pseudomonas aeruginosa in bronchiectasis: infection, inflammation, and therapies. Expert Rev Respir Med. 2021;15:649–62. doi: 10.1080/17476348.2021.1906225. [DOI] [PubMed] [Google Scholar]
- 29.Hsieh MH, Lin CY, Wang CY, Fang YF, Lo YL, Lin SM, et al. Impact of concomitant nontuberculous mycobacteria and Pseudomonas aeruginosa isolates in non-cystic fibrosis bronchiectasis. Infect Drug Resist. 2018;11:1137–43. doi: 10.2147/IDR.S169789. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Kamata H, Asakura T, Suzuki S, Namkoong H, Yagi K, Funatsu Y, et al. Impact of chronic Pseudomonas aeruginosa infection on health-related quality of life in Mycobacterium avium complex lung disease. BMC Pulm Med. 2017;17:198. doi: 10.1186/s12890-017-0544-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Vidaillac C, Yong VF, Jaggi TK, Soh MM, Chotirmall SH. Gender differences in bronchiectasis: a real issue? Breathe (Sheff) 2018;14:108–21. doi: 10.1183/20734735.000218. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Zhou YY, Wang YH, He SQ, Wang WY, Wang XY, Li DS, et al. Gender differences in clinical characteristics of patients with non-cystic fibrosis bronchiectasis in different age groups in northern China. Clin Respir J. 2023;17:311–9. doi: 10.1111/crj.13596. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Chien J, Hwang JH, Nilaad S, Masso-Silva JA, Ahn SJ, McEachern EK, et al. Cigarette smoke exposure promotes virulence of Pseudomonas aeruginosa and induces resistance to neutrophil killing. Infect Immun. 2020;88:e00527–20. doi: 10.1128/IAI.00527-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Drannik AG, Pouladi MA, Robbins CS, Goncharova SI, Kianpour S, Stampfli MR. Impact of cigarette smoke on clearance and inflammation after Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2004;170:1164–71. doi: 10.1164/rccm.200311-1521OC. [DOI] [PubMed] [Google Scholar]
- 35.Chin KL, Sarmiento ME, Alvarez-Cabrera N, Norazmi MN, Acosta A. Pulmonary non-tuberculous mycobacterial infections: current state and future management. Eur J Clin Microbiol Infect Dis. 2020;39:799–826. doi: 10.1007/s10096-019-03771-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Comparison of clinical characteristics of NTM-PD patients with or without Klebsiella pneumoniae cultured from bronchial washing fluid.
Comparison of clinical characteristics of NTM-PD patients with or without Staphylococcus aureus cultured from bronchial washing fluid.

